Feedback
  • Corrigendum: BI 1015550 is a PDE4B inhibitor and a clinical drug candidate…

Corrigendum: BI 1015550 is a PDE4B inhibitor and a clinical drug candidate for the oral treatment of idiopathic pulmonary fibrosis

Affiliation
Boehringer Ingelheim Pharma GmbH & Co. KG ,Biberach an der Riss ,Germany
Herrmann, Franziska Elena;
Affiliation
Boehringer Ingelheim Pharma GmbH & Co. KG ,Biberach an der Riss ,Germany
Hesslinger, Christian;
Affiliation
Boehringer Ingelheim Pharma GmbH & Co. KG ,Biberach an der Riss ,Germany
Wollin, Lutz;
Affiliation
Boehringer Ingelheim Pharma GmbH & Co. KG ,Biberach an der Riss ,Germany
Nickolaus, Peter

Category

Published in:
Frontiers in Pharmacology
Vol. 14 (30.05.2023)
Volume:
14
Date Issued:
30.05.2023
DOI:
10.3389/fphar.2023.1219760
Language:
English
Type of Resource:
Text
Keywords:
PDE4B; IPF; lung fibrosis; phosphodiesterase; cAMP; ILDs
Subject of DNB:
610 Medical sciences Medicine

Cite

Citation style:
Could not load citation form.

Access Statistic

Total:
Downloads:
Abtractviews:
Last 12 Month:
Downloads:
Abtractviews:
open graphic

Rights

License Holder: Copyright © 2023 Herrmann, Hesslinger, Wollin and Nickolaus.

Use and reproduction: